Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a ...

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, ...

Escalating adjuvant treatment based on ctDNA positivity does not improve RFS in patients with stage III colon cancer, data suggest.